Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study

Pieternella Lugtenburg Irit Avivi 1 Henriette Berenschot Osman Ilhan Jean Pierre Marolleau 2 Arnon Nagler 3 Antonio Rueda Monica Tani Mehmet Turgut Stuart Osborne Rodney Smith Michael Pfreundschuh 4 Adrian Tempescul 5
1 Tel Aviv Sourasky Medical Center [Te Aviv]
2 CHU - Centre Hospitalier Universitaire d'Amiens
3 Service d'Hématologie [AP-HP Hôpital Saint-Antoine]
4 Saarland University Medical School
5 CIC Brest
Document type :
Journal articles
Complete list of metadatas
https://hal.univ-brest.fr/hal-02049783
Contributor : Ghislaine Calvez <>
Submitted on : Tuesday, February 26, 2019 - 4:10:29 PM
Last modification on : Wednesday, February 27, 2019 - 1:09:41 AM

Identifiers

  • HAL Id : hal-02049783, version 1

Collections

UNIV-BREST

Citation

Pieternella Lugtenburg, Irit Avivi, Henriette Berenschot, Osman Ilhan, Jean Pierre Marolleau, et al.. Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study. Haematologica, Ferrata Storti Foundation, 2017, 102 (11), pp.1913-1922. ⟨hal-02049783⟩

Export

BibTeX TEI DC DCterms EndNote

Share

Metrics

Record views

38

Contact

CCSD